FDA Highlights Potential Benefits Of OTC Monograph User Fees
This article was originally published in The Rose Sheet
Executive Summary
FDA schedules a public meeting June 10 and opens a docket for stakeholder input on the potential development of a user-fee program for OTC monograph drugs. CDER points out the OTC monograph is "one of the largest and most complex regulatory programs ever undertaken at FDA."